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ABSTRACT
Objectives: The role of angiogenesis in leiomyosarcomas still remains unclear. The aim of this study was to evaluate the 
NRP1 expression in the leiomyosarcoma tissues and to find the relations between its expression and the clinical features.
Material and methods: The study group consisted of 50 patients with diagnosis of the uterine leiomyosarcoma. Clinical 
and follow up data were collected. Using immunohistochemical methods the expression of NRP1 was detected. 
Results: The lack of NRP1 expression was found in 14 cases, positive (weak or moderate) expression was noted in 36 cases. The 
significantly higher expression of NRP1 was observed in more severe clinical stages in comparison to lower stages of the 
disease. The significantly shorter survival of patients with the positive expression of NRP1 in leiomyosarcoma was observed. 
Conclusions: The expression of NRP1 is associated with clinical advancement and worse prognosis in uterine LMS. Neuropilin 
1 can be widely used as a postoperative survival predictor for the patients suffering from uterine LMS.
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INTRODUCTION
Uterine leiomyosarcomas (LMS) constitute a rare type of 
female reproductive organs tumors. It is a heterogeneous 
group of cancers whose common feature is the histological 
origin from the mesenchymal tissues. These tumors are 
characterized by the dynamic development, the capacity 
to metastasize and postoperative recurrence [1]. The most 
common histological type of uterine sarcoma is leiomyosar-
coma which is diagnosed in 1 to 8.4% of malignant uterine 
tumors [2, 3].
The cells with the high dynamics of the metabolic pro-
cesses, such as cancer cells require permanent supplies in 
substrates and the discharge of metabolic products for 
their development, and most of all, for their mitotic activity. 
The process of angiogenesis often occurs simultaneously 
with the formation of lymphatic vessels [4]. The process of 
tumor angiogenesis has been the subject of many studies, 
meanwhile the processes of lymphatic vessels growth, for-
mation of lymph nodes metastases and lymphangiogenesis 
induced by the tumor are still much less understood. Both 
lymphatic and blood vessels seem to play a crucial role 
in maintaining homeostasis in cancer cells. As is widely 
known, many cancers metastasize to lymphatic nodes pre-
dominantly so the development of the cancerous lymphatic 
vessels seems to be crucial for their spreading. The invasion 
of the lymphatic nodes constitutes a prognostic factor in 
some types of cancer such as melanoma, breast and prostate 
cancer [5]. VEGF family of proteins, especially VEGF-C and 
VEGF-D and their binding to VEGFR-3 [6, 7] play crucial role 
in the process of lymphangiogenesis. The recent research 
results indicate also a vital role of neuropilin family in the 
regulation of this process. 
Neuropilins are a group of transmembrane proteins with 
a molecular weight of approx. 130 kDa. They serve as recep-
tors for many important factors regulating cell metabolism. 
These are VEGF proteins, class 3 semaphorins, PlGF-2, FGF, 
HGF, PDGF, TGF-β [8]. Physiologically, neuropilins appear 
on the surface of many types of cells such as endothelium 
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of blood and lymphatic vessels, T lymphocytes, nerve cells, 
keratinocytes. Neuropilins are expressed in certain types of 
cancers, of both epithelial and mesenchymal origins (e.g.: 
certain leukemias, malignant melanoma, pancreatic cancer, 
osteosarcoma, tumors of the gastrointestinal tract) [9, 10]. 
The presence of the NRP has been demonstrated in many 
other malignant tumors, including lung cancer or malignant 
gliomas [11–13]. Neuropilin family consists of two proteins 
encoded by two separate genes NRP 1 (located in 10p12) 
and NRP 2 (located in 2q34) [14]. In spite of the structural 
similarities, both neuropilins have an affinity for different li-
gands. Neuropilin 1 binds to VEGF-A, PIGF2, SEMA3A, SEMA3B 
semaphorins and SEMA3E. On the other hand, neropilin 
2 indicates greater affinity to VEGF-C, VEGF-D, SEMA3F and 
SEMA3G semaphorins [8]. It should be noted that different 
ligands which bind to neuropilins compete with each other. 
This information can be used when planning future targeted 
cancer therapies due to the fact that neuropilins combined 
with different ligands can activate various cell pathways. An 
example of such relation is the competitive binding of neuro-
pilin 1 with VEGF and class 3 semaphorin. In the first case, with 
the contribution of VEGFR-2, the endothelial cells migration 
is stimulated. In the second case, neuropilin 1 together with 
plaxin A causes the opposite reaction [15].
Neuropilins play also an important role in the angiogen-
esis and lymphangiogenesis processes. Neuropilin 1 shows 
a co-receptor activity for VEGFR-2 facilitating its binding to 
VEGF (VEGF A), on the other hand, neuropilin 2 performs this 
function for VEGFR-3 and its ligands VEGF-C i VEGF-D [16]. 
What seems to be interesting is the influence of the proteins 
from the VEGF family onto mutual neuropilins location and 
VEGF receptors. It has been shown that the exposure on 
the endothelial growth factors influences the neuropilin 
location in the vicinity of VEGF receptors [17]. During lym-
phangiogenesis neuropilin 1 is involved in the formation of 
lymphatic vessel valves as a receptor for class 3 semaphorins 
The expression of neuropilin 2 is higher in endothelial cells 
and together with VEGF-C ligand it influences budding and 
growth of lymphatic vessels [18].
OBJECTIVES
The aim of this study was to evaluate the neuropilin 
1 expression in the leiomyosarcoma tissues and to find the 
relations between its expression and the clinical stage of 
the disease and the overall survival of patients .
MATERIAL AND METHODS
The study group consisted of 50 patients with the uteri-
ne leiomyosarcoma diagnosis, operated in the 1st Chair and 
Department Of Gynaecological Oncology and Gynaecology 
Medical University in Lublin, in 2000–2013. The average age 
of patients was 52.84 years old (median 51.50, SD 12.36, 
min. 29, max. 76). The ethnicity of all of the patients in study 
group were white, non hispanic, non latino. The patients 
were enrolled to the study retrospectively. In each case, the 
degree of clinical stage was evaluated according to FIGO 
classification effective from 2009 on the basis of surgeries 
descriptions and histopathological examination [19]. 
46 (92%) of patients underwent total hysterectomy and 
bilateral salpingoopherectomy. In two cases (4%) the surge-
ry was limited to tissue sampling, 1 patient (2%) underwent 
total hysterectomy without adnexectomy, in another case 
(2%) retroperitoneal tumor was resected.
Immunohistochemistry
From the paraffin blocks containing representative pieces 
of tissue taken from leiomyosarcoma the microscopic prepa-
rations were made. The immunohistochemical examinations 
were made on the scraps measuring 4 μm. After dewaxing 
and hydration of the tissue material in the alcohol series, the 
procedure of unveiling antigenic determinant was applied by 
using EnVision FLEX Target Retrieval Solution High pH (50x) 
buffer, (Dako, Cat. No. K8000 ) for 40 minutes. Endogenous 
peroxidase activity was blocked with 3% sodium dihydrogen 
dioxide for 5 minutes at room temperature. The preparations 
were washed every time 3 × 5 min in EnVision Flex Wash 
Buffer (20x) (DAKO , Cat. No. K800721) and incubated with 
the primary antibody directed against an examined antigen 
NRP 1. In the studies, monoclonal mouse antibodies targeted 
against human protein neuropilin1 were used (Santa Cruz 
Biotechnology, USA) and a stain set DAKO EnVision+ System 
Kit with the secondary antibody conjugated with peroxidase. 
The color reaction was achieved after approx. 3 minutes 
of incubation at room temperature. Next, the cells nuclei 
were stained with the use of Mayer’s hematoxylin. When 
performing a negative control, a procedure similar to that 
in the primary reaction was applied yet without the primary 
antibody. The reactions were evaluated with the use of light 
microscope Carl Zeiss Axiostar plus (Germany). 
To evaluate the immunohistochemical reaction for neu-
ropilin 1, a qualitative scale was adopted, based on the 
percentage of tumor cells exhibiting a color reaction [20],
• 0 — lack of cytoplasmic color reaction in cells,
• 1 — weak cytoplasmic staining in ≤ 10% of cells,
• 2 — moderate cytoplasmic staining in > 10–50% of cells,
• 3 — strong cytoplasmic staining in > 50% of cells.
The statistical analysis 
The statistical analyses were prepared with the use of 
SPSS program, 14PL version. Qualitative variables (neuro-
pilin 1 expression) were evaluated by the Chi2 and Fisher’s 
tests. The correlations among variables were evaluated by 
the Spearman’s test. The distribution of survival times were 
analyzed using the Kaplan-Meier method. The differences 
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of survival times distributions in the studied groups were 
analyzed by the log-rank test (Mantel-Cox). The differences 
or relations between variables were considered as statisti-
cally significant at p < 0.05.
RESULTS
The lack of neuropilin 1 expression was found in 14 ca-
ses (28%) of leiomyosarcoma, positive (weak or moderate) 
expression was noted in 36 cases (72%). There was no strong 
neuropilin expression found. The examples of typical im-
munohistochemical staining results of the representative 
samples of leiomyosarcoma are presented in Figures 1–3.
For the statistical aims, the neuropilin 1 expression was 
recognized as qualitative variable and analyzed in two ways:
• analysis 1: 0 — no expression vs 1 — expression i.e. 
from 1 to 2 (weak and moderate),
• analysis 2: 1 — no expression or weak expression i.e. 
from 0 to 1 vs 2 — moderate expression. The positive correlation was found between intensity of 
neuropilin 1 expression (no expression vs expression) and 
stage of disease (p = 0.092). There were no significant diffe-
rences (p = 0.111) in neuropilin 1 expression (no expression 
vs expression) depending on the degree of the disease stage 
considering the FIGO I + II and FIGO III + IV classification 
analyzed together. The significant differences (p = 0.015) 
in neuropilin 1 expression were noted (no expression or 
weak expression vs moderate expression) depending on 
the degree of the disease stage analyzed separately. The si-
gnificantly higher (p = 0.002) expression of neuropilin 1 was 
observed in more severe clinical stages of leiomyosarcoma 
(FIGO III and IV) in comparison to lower degrees of disease 
stages (FIGO I and II) (Tab. 1 and 2).
While evaluating the relations between neuropilin 1 
expression and an overall survival of patients, the significan-
tly shorter (p = 0.018) survival of patients with the positive 
expression of neuropilin 1 in leiomyosarcoma was observed 
(Fig. 4). Significantly shorter (p = 0.006) survival of patients 
with the moderate expression of neuropilin 1 was demon-
strated in comparison to patients with a lack of expression 
or low expression of this protein in leiomyosarcoma. The 
significantly higher neuropilin 1 expression was observed 
among patients of less than or equal to 2 years of survival, 
in comparison with patients with the survival rate more 
than 2 years. The significantly higher (p = 0.011) neuropilin 1 
expression was noted in the group of patients with the 
survival rate less than or equal 2 years, in comparison with 
patients of the survival rate longer than 2 years (Tab. 3).
DISCUSSION
Among malignant cancers of female reproductive or-
gans, LMS is one of those which appears rarely. In spite 
of the unquestionable progress which has been made in 
oncology for the past few years, both diagnostic process 
Figure 1. Negative immunohistochemical reaction to neuropilin 1 
in leiomyosarcoma cells (Dako EnVision+ System-HRP; 20× lens 
magnification)
Figure 2. Weak positive cytoplasmic immunohistochemical reaction 
to neuropilin 1 in leiomyosarcoma cells (Dako EnVision+ System-HRP; 
20x lens magnification)
Figure 3. Moderately intensive positive cytoplasmatic 
immunohistochemical reaction to neuropilin 1 in leiomyosarcoma 
cells (Dako EnVision+ System-HRP; 20x lens magnification)
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and the therapy as well as the results of treatment of le-
iomyosarcoma have not changed. Still, the main method 
of treatment is radical surgical excision of tumors and the 
effectiveness of adjuvant therapy still remains questionable. 
The reason behind this can be traced to the insufficient 
knowledge of the biology of this group of tumors, which in 
turn results from their rarity and heterogeneity. The biology 
of leiomyosarcoma differs significantly from the biology of 
better-known cancers of epithelial origin. 
In the literature various survival rates of patients suf-
fering from uterine LMS are mentioned, most of reported 
rates of 5 years disease specific survival vary from 4 to abo-
ut 70 percent [21]. The results obtained in the study may 
seemed to be unexpectedly good, 72 percent of patients 
survived longer than 2 years after diagnosis. It can be expla-
ined by the fact that most of them underwent complete 
tumor resection.
In several studies the formation of blood vessels has 
been widely recognized as a critical process in the growth 
of cancerous tumors. The process of angiogenesis is ac-
companied by the dynamic development of the lymphatic 
vessels, called lymphangiogenesis. The role of assessment 
and the potential usefulness of examining the networks of 
microvessels in LMS is so far poorly understood. One of the 
markers of the process of the lymphatic vessels creation is 
neuropilin 1, present in a mature endothelium of the lym-
phatic system. It has been shown that the overexpression 
of this protein in the cancerous tissue is a poor prognostic 
factor in many malignant tumors [22].
Neuropilin 1 is an important receptor that participates in 
the regulation of metabolism and the cells migration. In the 
majority of examined uterine leiomyosarcoma, the positive 
Table 1. Neuropilin 1 expression depending on the disease stage according to FIGO (IA–IV)
N No expression Expression p*
FIGO IA 10 6 (60.0%) 4 (40.0%)
0.092
FIGO IB 23 6 (26.1%) 17 (73.9%)
FIGO II 6 1 (16.7%) 5 (83.3%)
FIGO III 5 1 (20.0%) 4 (80.0%)
FIGO IV 6 0 (0.0%) 6 (100.0%)
FIGO I + II 39 13 (33.3%) 26 (66.7%) 0.111
FIGO III + IV 11 1 (9.1%) 10 (90.9%)
P* — the significance was calculated with the use of Chi2 test
Table 2. Neuropilin 1 expression (no expression or weak expression vs moderate expression) depending on disease stage according to FIGO 
classification
N No expression or weak expression Moderate expression p*
FIGO IA 10  8 (80.0%) 2 (20.0%)
0.015
FIGO IB 23 13 (56.5%) 10 (43.5%)
FIGO II 6 4 (66.7%) 2 (33.3%)
FIGO III 5 1 (20.0%) 4 (80.0%)
FIGO IV 6 0 (0.0%) 6 (100.0%)
FIGO I + II 39 25 (64.1%) 14 (35.9%) 0.002
FIGO III + IV 11 1 (9.1%) 10 (90.9%)
P* — the significance was calculated with the use of Chi2 test
Figure 4. The cumulative survival function according to Kaplan-
Meier for patients with leiomyosarcoma depending on neuropilin 1 
expression. The trimmed mean (+), (no expression + weak expression 
vs moderate expression)
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expression of this protein was discovered. While analyzing 
the material statistically, the positive correlation between the 
increased expression of neuropilin 1 and the clinical stage 
of the disease was noted. The upward trend of this protein 
expression increase with the development of the disease was 
also observed. Moreover, a negative correlation between the 
neuropilin 1 expression and the LMS patients survival time 
was observed. Similar results were achieved by Lu et all. who 
analyzed the correlations between neuropilin 1 expression 
and patients survival and the clinical stage of malignant mela-
noma [23]. Neuropilin 1 was identified as a prognostic factor in 
the ovarian cancer in which the positive correlation between 
its expression and a degree of clinical stage according to 
FIGO was also observed [24]. The results and the analysis of 
the available literature, led to conclusion that NRP1 may in 
the future be a potential prognostic factor in the LMS. It is 
worth noting that the immunohistochemical assessment of 
neuropilin 1 expression is a relatively easily available method 
and can be routinely used as an element of histopathological 
examination. The presence of NRP 1 overexpression in leiomy-
osarcoma apart from the prognostic value, can be also used 
in planning future therapies. Nowadays, the studies focus on 
the use of antibodies against NRP 1 as components of immu-
noliposomes containing cytotoxic drug in their interior. They 
presents the ability ot selectively bind with cells that have NRP 
1 on its surface. The aim of creating immunoliposomes con-
taining antibodies against proteins whose expression is high 
on the surface of cancer cells is enabling the selective uptake 
by the cancer cells which in turn increases the concentration 
of the drug in the tumor. Such a procedure on one hand, has 
a chance to lead to the reduction of cancer therapy toxicity 
(by reducing the concentration of the drug in other tissues), 
and on the other hand, to boost its effectiveness by significant 
increase of cytostatic concentration in the tumor. The studies 
on the use of immunoliposoms containing in their interior 
docetaxel and on the surface antibodies against neuropilin 
1 was conducted on melanoma and lung cancer models by 
Manjappa et all. [25]. They observed the selective uptake 
of liposomes by the cells of both cancers which resulted in 
the increase of drug cytotoxicity. Moreover, they noted the 
significant decrease of microvessel density in the tumors that 
were treated with liposomes. The above observations may 
suggest that apart from the increase of drug concentration 
tumors which results in the increase of cytotoxic effect, the 
use of antibodies against neuropilin 1 limits the angiogenesis 
process intensification. Such an action can be attributed to 
the deterioration of the neuropilin function in the cancer cells 
metabolism as well as in endothelial cells.
Taking into account the results of the studies concerning 
the neuropilin 1 expression in leiomyosarcoma, it seems 
reasonable to conduct research on possibilities of therapy 
with the use of immunoliposoms containing antibodies 
anti-neuropilin 1, especially with reference to LMS in severe 
clinical stages of the disease. The introduction of this kind 
of therapy has a chance to improve treatment results, espe-
cially in the cases in which the tumor total surgical resection 
is impossible. In the conducted research, especially high 
expression of NRP 1 was observed in tumors of a severe 
clinical stage which appears to prove the possibility of using 
such therapies in these cases. 
CONCLUSIONS
On the basis of the study, the following conclusions 
were made:
1. The expression of NRP1 is associated with clinical ad-
vancement and worse prognosis in uterine LMS.
2. Neuropilin 1 can be widely used as a postoperative sur-
vival predictor for the patients suffering from uterine LMS.
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Table 3. Neuropilin 1 expression in the groups of patients depending on their 2-year survival
Survival ≤ 2 years Survival > 2 years p*
N 14 36
No expression or weak expression 3 (21.4%) 11 (78.6%)
0.011
Moderate expression 23 (63.9%) 13 (36.1%)
No expression 0 (0.0%) 14 (38.9%) 0.005
Expression 14 (100.0%) 22 (61.1%)
P* — the significance was calculated with the use of Fisher’s test
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